



GP/1653

PATENT

Attorney Docket No. A-68752-1/RFT/RMK

UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 19 2001

TECH CENTER 1600/290

In re application of:

HAMMERMAN, et al.

Serial No.: 09/472,662

Filed: December 27, 1999

For: COMPOSITION AND METHOD
FOR IMPROVING FUNCTION
OF EMBRYONIC KIDNEY
TRANSPLANTS

Examiner: F. MOEZIE

Art Unit: 1653

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed
enclosures, is being deposited with the United States Postal
Service as First Class Mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington,
D.C. 20231 on April 9, 2001

Signed:

Suzan Lindstrom

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This amendment is in response to the Restriction Requirement mailed March 9, 2001. It is submitted on or before the due date of April 9, 2001, making it a timely response.

In response to the outstanding Restriction Requirement in this application, Applicants restrict the claims for further prosecution to the claims of Invention II, claims 3-10, drawn to embryonic metanephric tissue which has been pre-treated and a method for the treatment of metanephric tissue.

Applicants are also required to elect a single disclosed species of growth factor as cited in claims 2, 4, 6, or 12 for prosecution on the merits. In response to this requirement, applicants elect vascular endothelial growth factor.

Claims 3-10 read on the species elected.

This election is made without traverse with the understanding that upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species, including claims 11-12.

In addition, prior to examination, please amend the above-identified application as follows:

In the Claims:

Please cancel claims 1 and 2.